Search

everythinglearnresearchcommunity

for

Search:↓

A user increased their RU58841 treatment from 5% to 8% to combat hair loss and is questioning the effectiveness of the higher dosage. Another user shared their extensive hair loss treatment regimen, suggesting that while 8% RU58841 might not significantly change results, it's worth trying as individual responses vary.

The conversation discusses a 4-month hair regrowth protocol that includes finasteride (1.25mg), RU58841, dermarolling, ketoconazole, minoxidil, peppermint oil, and fatty acids/oils. Progress pictures are shared to show the results of these treatments.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

User experienced shortness of breath, high blood pressure, red eyes, and eye floaters after using RU58841 for hair loss. They warn others to avoid RU58841 and stick to finasteride, minoxidil, and dutasteride.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

Affordable 92-LED caps may be more effective for hair growth than expensive 270-laser caps due to higher power output and irradiance. The LED caps deliver more energy to the scalp, making them a cost-effective alternative for red light therapy.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.

The conversation discusses whether finasteride would still be necessary if Verteporfin becomes a successful hair loss treatment. It also explores the sensitivity of transplanted hair to DHT and the potential for off-label use of Verteporfin post hair transplant.

The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.

A user shared their experience with hair loss treatments, including RU58841, ketoconazole shampoo, caffeine shampoo, and topical finasteride. They found RU58841 effective for diffuse thinning but experienced severe hair loss after stopping it; topical finasteride worked well for a receding hairline but caused side effects. They also use a charcoal shampoo and practice scalp massages.

A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.

RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.

A user is considering using RU58841 to treat hair loss and asks if it can be effective for 4-5 years. Some suggest starting with a lower concentration and debate the safety of RU58841 compared to approved drugs like finasteride.

Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.

The conversation is about hair loss treatment progress using a combination of 0.1% finasteride, 0.025% tretinoin solution, and 2.5mg oral minoxidil. Users express positive reactions and hope for similar results.

A user with hair loss is considering starting a business selling hair loss treatments, including RU58841, low-dose topical finasteride with optional minoxidil and tretinoin, and topical melatonin. They are also contemplating offering Pyrilutamide and other unique topicals, seeking feedback on interest and suggestions for their potential store.

The user has been using finasteride, minoxidil, a dermastamp, and red light therapy for six months with no visible improvement since the three-month mark. Other users noted improvement, particularly in the left temple area, and encouraged the user to continue.

The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.

Treatments for hair loss, specifically discussing the use of RU58841 and Pyrilutamide from Actifolic. The poster is inquiring about experiences with these products and results.

RU-58841 does not dissolve well in common Minoxidil solutions due to water content, requiring a 70/30 ethanol/propylene glycol mix. Users report using separate solutions for RU-58841 and finasteride/Minoxidil for better results.

The user is seeking a quicker-drying carrier for RU58841 and Minoxidil to improve adherence to their hair loss treatment routine. They want to apply it after a morning shower without affecting their hair's appearance.

A user shared their positive experience with the telehealth service DocBright, highlighting its affordability and effectiveness in prescribing finasteride, oral minoxidil, and ketoconazole. They noted the service's unique ability to provide a prescription at age 17 but criticized the unprofessional communication with the dermatologist.

A user stopped using RU58841 after discovering their girlfriend's unplanned pregnancy, expressing concern about potential harm to the baby. Others advised consulting a doctor, waiting for health scans, and considering switching to oral finasteride or natural supplements like saw palmetto.

A user shared their success in getting a prescription for 0.1% Alfatradiol, a topical treatment for hair loss similar to finasteride but with fewer side effects. They found a pharmacy to compound it and will update on the results.

Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.

The user has been using finasteride for a year to stop hair loss and is considering adding RU58841 instead of minoxidil to further inhibit DHT. Another user suggests adding dutasteride for better DHT inhibition, but the original user cannot access it and is considering RU58841 despite potential side effects.

User asks about CB-03-01 for hair loss treatment and mentions using topical Dutasteride, TRT, and considering mixing CB-03-01 with Fluridil. CB-03-01 is sold at a high price, and user considers trying a lower concentration.

RU58841 should be applied directly to the scalp, ideally once a day, a few hours before bed. Some users experienced side effects like shedding and systemic issues when using RU58841 and Minoxidil together, while others reported no side effects when using RU58841 alone.

Actifollic selling Pyrilutamide as a treatment for hair loss, with people debating its efficacy compared to Minoxidil and Finasteride in combination with RU58841.